In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since…
A recent comprehensive study, published in The Lancet Neurology, has revealed staggering figures regarding neurological conditions worldwide. In 2021, over 3 billion individuals were found to be living with such…
Amidst the escalating challenges posed by environmental pollution and climate change, the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) have joined forces to launch a new…
The latest publication from the World Health Organization (WHO), titled “Equity in Health and Care: Gender Dynamics in Undervalued Health and Care Labor,” sheds light on how gender disparities within…
Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study,…
Lupin Limited, a global pharmaceutical powerhouse, has secured approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application concerning Doxycycline for Injection USP,…
The Role of Quality Control at Orion Pharmaceuticals Maija Blomquist, the Quality Control Manager for Materials, Gels & Ointments, underscores the pivotal role of quality control in maintaining Orion’s product…
Unlocking Project Management’s Role in CDMOs In the intricate web of pharmaceutical and biotech industries, Contract Development and Manufacturing Organizations (CDMOs) stand as pivotal partners, offering indispensable services like API…
Blueprint Medicines Corporation (Nasdaq: BPMC) has announced that as of March 1, 2024, the Compensation Committee of its Board of Directors has approved the granting of non-qualified stock options to…
CRISPR Therapeutics, a leading biopharmaceutical firm dedicated to pioneering gene-based treatments for severe illnesses, has unveiled its proposal to appoint Christian Rommel, Ph.D., to its Board of Directors during the…
UCB, a global biopharmaceutical company, has unveiled the findings of 48-week post-hoc analyses derived from pooled Phase 3 data originating from the BE HEARD I and BE HEARD II trials.…
Amgen Unveils New Research on Otezla® (Apremilast) at AAD 2024 Amgen, a leader in biotechnology, has disclosed fresh findings from the Phase 3 SPROUT trial, investigating Otezla® (apremilast) in children…